

Jim Doyle Governor

Kevin R. Hayden Secretary

Department of Health and Family Services

1 WEST WILSON STREET P O BOX 2659 MADISON WI 53701-2659

> 608-266-1251 FAX: 608-267-2832 TTY: 888-701-1253 dhfs.wisconsin.gov

January 31, 2008

RE: CDC Health Advisory Influenza-Associated Pediatric Mortality and *Staphylococcus aureus* co-infection CDC Recommendations and Case Reporting

#### **CDC Recommendations:**

- Health care providers should test persons hospitalized with respiratory illness for influenza, including those with suspected community-acquired pneumonia.
- Health care providers should be alerted to the possibility of bacterial co-infection among children with influenza, and request bacterial cultures if children are severely ill or when community-acquired pneumonia is suspected.
- Health care providers should be aware of the prevalence of methicillin-resistant *S. aureas* (MRSA) strains in their communities when choosing empiric therapy for patients with suspected influenza-related pneumonia.

### **Case Reporting:**

Since 2004, Influenza-Associated Pediatric Deaths have been a nationally reportable condition. The Department of Health and Family Services will make Influenza-Associated Pediatric Deaths reportable in Wisconsin, beginning March 1, 2008.

#### Case definition:

- An influenza-associated death is defined for surveillance purposes as a death resulting from a clinically compatible illness that was confirmed to be influenza by an appropriate laboratory or rapid diagnostic test.
- There should be no period of complete recovery between the illness and death.
- Influenza-associated deaths in all persons aged <18 years should be reported.

#### Laboratory criteria for diagnosis:

Laboratory testing for influenza virus infection may be done on pre- or post-mortem clinical specimens, and include identification of influenza A or B virus infections by a positive result by at least one of the following:

- Influenza virus isolation in tissue cell culture from respiratory specimens
- Reverse-transcriptase polymerase chain reaction (RT-PCR) testing of respiratory specimens
- Immunofluorescent antibody staining (direct or indirect) of respiratory specimens
- Rapid influenza diagnostic testing of respiratory specimens

- Immunohistochemical (IHC) staining for influenza viral antigens in respiratory tract tissue from autopsy specimens
- Four-fold rise in influenza hemagglutination inhibition (HI) antibody titer in paired acute and convalescent sera. Serologic testing for influenza is available in a limited number of laboratories, and should only be considered as evidence of recent infection if a four-fold rise in influenza antibody titer is demonstrated in paired sera. Single serum samples are not interpretable.

Attached are the CDC influenza-associated pediatric case report form.

Completed reports should be faxed to the Wisconsin Division of Public Health at (608) 261-4976. The Division of Public Health will be responsible for sending data to the CDC, and for assuring notification of local public health officials regarding data received from local healthcare providers, coroners and Medical Examiners.

Questions and clarification of reporting mechanisms and case consultation should be addressed to:

Thomas Haupt M.S. Wisconsin Division of Public Health hauptte@dhfs.state.wi.us 608-266-5326



# **Influenza-Associated Pediatric Deaths Case Report Form**

Form approved OMB No. 0920-0007

STATE USE ONLY – DO NOT SEND INFORMATION IN THIS SECTION TO CDC								
Last Name:	First Name:		County:					
Address:	City:	City:						
Patient Demographics								
1. State: 2. Cou	nty:	3. State ID:	4. CDC ID:					
5. Age:	e of birth:/ MM DD	7.Sex: ☐ Male ☐ Female	1	☐ Hispanic or Latino ☐ Not Hispanic or Latino ☐ Unknown				
9. Race: ☐ White ☐ Black ☐ Asian ☐ Native Hawaiian or Other Pacific Islander ☐ American Indian or Alaska Native ☐ Unknown								
Death Information								
10. Date of illness onset:/ / 11. Date of death:/ / to CDC?    MM   DD   YYYY								
Influenza Testing (check all that were used)  Specimen								
Test Type		Collection Date						
☐ Commercial rapid diagnostic test	☐ Influenza A☐ Influenza A/B (Not Disti	/						
☐ Viral culture	☐ Influenza A (Subtyping I☐ Influenza A (Unable To	/						
☐ Direct fluorescent antibody (DFA)	□ Influenza A □ Influenza A/B	/						
☐ Indirect fluorescent antibody (IFA)	☐ Influenza A ☐ Influenza A/B	//						
☐ Enzyme immunoassay (EIA)	☐ Influenza A (Subtyping Not Done) ☐ Influenza B ☐ Negative ☐ Influenza A (Unable To Subtype) ☐ Influenza A (H1) ☐ Influenza A (H3)							
□ RT-PCR	☐ Influenza A (Subtyping I☐ Influenza A (Unable To	//						
☐ Immunohistochemistry (IHC)	□ Influenza A	//						



# **Influenza-Associated Pediatric Deaths Case Report Form**

Culture confirmation of INVASIVE bacterial pathogens							
14 a. Was a specimen collected for bacterial culture from a normally sterile site (e.g., blood, cerebrospinal fluid [CSF], tissue, or pleural fluid)? ☐ Yes ☐ No ☐ Unknown							
14 b. If yes, please indicate the site from which the specimen was obtained.  □ Blood Date// □ Positive □ Negative □ Unknown □ Pleural fluid Date// □ Positive □ Negative □ Unknown □ CSF Date// □ Positive □ Negative □ Unknown □ Other Date// □ Positive □ Negative □ Unknown □ Unknown							
14 c. What was the result of the bacteri	ial culture?	☐ Positive ☐ Negative ☐ Unknown					
14 d. If positive, please check the organism cultured.							
☐ Streptococcus pneumoniae	☐ Staphylococcus aureus, methicillin sensitive	□ Neisseria meningitidis (serogroup, if known):					
☐ Haemophilus influenzae type b	☐ Staphylococcus aureus, methicillin resistant (MRSA)	☐ Group A streptococcus					
☐ Haemophilus influenzae not-type b	☐ Staphylococcus aureus, sensitivity not done	☐ Other invasive bacteria:					
Culture confirmation of bacter	rial pathogens from NON-STERILE SI	ΓES					
14 e. Were other respiratory specimens collected for bacterial culture (e.g., sputum, ET tube aspirate)? □ Yes □ No □ Unknown							
14 f. If yes, please indicate the site from which the specimen was obtained.  □ Sputum □ Date _/_/ □ Positive □ Negative □ Unknown □ ET tube □ Date _/_/ □ Positive □ Negative □ Unknown □ Other □ Date _/_/ □ Positive □ Negative □ Unknown □ Unknown							
14 g. What was the result of the bacter	ial culture?	☐ Positive ☐ Negative ☐ Unknown					
14 h. If positive, please check the organism cultured.							
☐ Streptococcus pneumoniae	☐ Staphylococcus aureus, methicillin sensitive	☐ Neisseria meningitidis (serogroup, if known):					
☐ Haemophilus influenzae type b	☐ Staphylococcus aureus, methicillin resistant (MRSA)	☐ Group A streptococcus					
☐ Haemophilus influenzae not-type b	☐ Staphylococcus aureus, sensitivity not done	☐ Other bacteria:					
Medical Care							
15. Did the patient receive medical care for this illness before admission to the hospital or death if outside the hospital? ☐ Yes* ☐ No ☐ Unknown							
16. If YES*, indicate level(s) of care received (check all that apply): □ Outpatient clinic □ ER □ Inpatient ward □ ICU							
17. Did the patient require mechanical ventilation? □ Yes □ No □ Unknown							



### **Influenza-Associated Pediatric Deaths Case Report Form**

Clinical Diagnoses and Complications								
18 a. Did complications occur during the acute illness: ☐ Yes ☐ No ☐ Unknown								
18 b. If yes, check all complications that occurred during the acute illness:								
☐ Pneumonia (Chest X-Ray	neumonia (Chest X-Ray confirmed)			☐ Croup	☐ Seizures			
☐ Bronchiolitis	□ Ence	☐ Encephalopathy/encephalitis		☐ Reye syndrome	☐ Shock ☐ Sepsis			
☐ Another viral co-infection	n:		☐ Other:					
19 a. Did the child have any medical conditions that existed before the start of the acute illness: ☐ Yes ☐ No ☐ Unknown								
19 b. If yes, check all medical conditions that existed before the start of the acute illness:								
☐ Moderate to severe developmental delay	☐ Hemaglobin	opathy (e.g. sickle cell d	lisease)	☐ Asthma/ reactive airway disease				
☐ Diabetes mellitus	☐ History of fe seizures	brile ☐ Seizure disc	☐ Seizure disorder ☐ Cystic fibrosis		sis			
☐ Cardiac disease (specify)		☐ Renal disea	se (specify)	Skin or soft	tissue infection			
☐ Chronic pulmonary disease (specify) ☐ Immunosuppressive condition (specify)								
☐ Metabolic disorder (specify)	☐ Metabolic disorder (specify) ☐ Neuromuscular disorder (including cerebral palsy) (specify)							
☐ Pregnant (specify gestational	☐ Other (spec	☐ Other (specify)						
<b>Medication and Therapy</b>								
20 a. Was the patient receiving any of the following therapies in the 7 days prior to illness onset or after illness onset? (check all that apply)  20 b. Was the patient receiving any of the following therapies prior to illness onset? (check all that apply)								
	NSAID or NSAID- ntaining products	☐ Antibiotic therapy ☐ Antiviral therapy specify	☐ Chemotherapy or radiation therapy	☐ Steroids by mouth or injection	☐ other immunosuppressive therapy:			
Influenza vaccine history	Influenza vaccine history							
21. Did the patient receive any influenza vaccine during the current season (before illness) ☐ Yes* ☐ No ☐ Unknown								
22. If YES*, please specify influenza vaccine received before illness onset:  □ Trivalent inactivated influenza vaccine (TIV) [injected] □ Live-attenuated influenza vaccine (LAIV) [nasal spray] □ Unknown								
23. If YES*, how many doses did the patient receive and what was the timing of each dose? (Enter vaccination dates if available)								
$\Box$ 1 dose $\Box$ <14 days prio ONLY $\Box$ ≥14 days prio	r to illness onset	Date dose given:MM	DD YYYY					
□ 2 doses onset	n <14 days prior to n ≥14 days prior to	Date of 1 <sup>st</sup> dose:MM	DD YYYY	Date of 2 <sup>nd</sup> dose	://			
24. Did the patient receive any influenza vaccine in previous seasons? ☐ Yes ☐ No ☐ Unknown								
Submitted By:Phone No.: ()E-mail Address:			Date: 	IM DD YYYY	<u> </u>			

Public reporting burden of this collection of information is estimated to average 20 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.